The FDA on May 8, 2025, granted accelerated approval to the combination of AVMAPKI® and FAKZYNJA® Co-pack, for adult patients with KRAS-mutated recurrent Low-Grade Serous Ovarian Cancer (LGSOC) who have received prior systemic therapy. AVMAPKI® and FAKZYNJA® are products of Verastem, Inc.
Bottom Ad
Advertisement
Subscribe
